Because IGF-1 LR3 is a growth-factor agonist that bypasses the bodys regulatory brakes on IGF signaling, the theoretical safety concerns discussed in the scientific literature deserve careful, non-alarmist attention
Ipamorelin vs GHRP-2 and GHRP-6 GHRP Family Side-by-Side Feature Receptor Ipamorelin GHS-R1a GHRP-2 GHS-R1a GHRP-6 GHS-R1a Feature Half-life Ipamorelin ~2 hours GHRP-2 ~25-30 minutes GHRP-6 ~20-30 minutes Feature Dosing Ipamorelin 1-3x daily (SubQ) GHRP-2 2-3x daily (SubQ) GHRP-6 2-3x daily (SubQ) Feature Standard dose Ipamorelin 100-300 mcg GHRP-2 100-300 mcg GHRP-6 100-300 mcg Feature Cortisol effect Ipamorelin None at standard doses GHRP-2 Yes GHRP-6 Yes Feature Prolactin effect Ipamorelin None GHRP-2 Moderate GHRP-6 Minimal Feature Appetite effect Ipamorelin Mild GHRP-2 Moderate GHRP-6 Strong Feature FDA status Ipamorelin Not approved GHRP-2 Not approved GHRP-6 Not approved All three target the same receptor
Stacking combining multiple peptides to create powerful synergy
Its core pathological feature is excessive accumulation of adipose tissue, accompanied by abnormal proliferation, differentiation, and metabolic dysfunction of adipocytes, which in turn induce a series of complications including insulin resistance, nonalcoholic fatty liver disease, and cardiovascular diseases
Hueso et al
The following article provides an overview of reports in 2018 and presents selected drug safety topics that were discussed within the DCGMA in this year
